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Abstract. The insulin-like growth factors (IGFs) have 
dramatic and complex effects on the growth of many 
tissues and have been implicated in both the prolifera- 
tion and differentiation of skeletal muscle cells. A  de- 
tailed analysis of gene expression was performed in 
L6E9 myoblast cultures treated with IGF-I to dissect 
the early events leading to the stimulation of myogenic 
differentiation by this growth factor. A  time course of 
transcript accumulation in confluent L6E9 myoblasts 
treated with defined media containing IGF-I revealed 
an initial transient decrease in myogenic factors, ac- 
companied by an increase in cell cycle markers and cell 
proliferation. This pattern was reversed at later time 
points, when the subsequent activation of myogenic 
factors resulted in a net increase in structural gene ex- 
pression and larger myotubes. The data presented here 
support the hypothesis that IGF-I activates prolifera- 
tion first, and subsequently stimulates events leading to 
the expression of muscle-specific genes in myogenic cell 
cultures. 
T 
HE activation of myogenic differentiation is the end 
point of a cascade of intracellular events, involving 
a  hierarchy of regulatory genes that remove myo- 
blasts  from the  cell cycle and  ultimately determine  the 
characteristic pattern of skeletal muscle gene expression. 
Once differentiated, adult muscle tissues retain the capac- 
ity to regenerate in response to exercise or injury by acti- 
vation and proliferation of satellite cells (41, 46). This pro- 
cess  is  presumably  influenced  by  extracellular  signals, 
which act locally to coordinate the regeneration process. 
Among the potential candidates for regulation of satellite 
cell function during regeneration is insulin-like growth fac- 
tor-I (IGF-I) (13, 37). 
The insulin-like growth factors (IGFs)  1 have been impli- 
cated in many anabolic pathways in  skeletal muscle, in- 
cluding protein synthesis, nucleic acid synthesis, and glu- 
cose uptake (for review see 20). The genes encoding IGF-I 
(70 amino acids) and IGF-II (67 amino acids) have been 
cloned and characterized (for review see 70). Both factors 
are clearly related to insulin at both the protein and nucleic 
acid levels. In the adult, IGF-I and IGF-II exert pleiotropic 
effects on numerous tissues, some of which mimic insulin 
action on cellular metabolism (for review see 43). IGF-I is 
distinct from insulin, however, in that it is synthesized by 
many tissues and has two major alternatively spliced iso- 
forms. 
Both  IGF-I  and  IGF-II  are  known  to  also  stimulate 
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myogenic differentiation in cell culture (14). Several mus- 
cle cell lines have been characterized that differ both in 
their patterns  of IGF synthesis and myogenic factor ex- 
pression. Although IGF-I expression is very low or nonex- 
istent in the neonatal rat L6 line and IGF-II is synthesized 
only at very low levels (59), the IGF-I receptor is present, 
rendering this cell line useful for the study of the effects of 
IGF-I on muscle. L6 cells are also restricted in their ex- 
pression profile of myogenic factors, and although myf-5 is 
present in myoblasts (5) and myogenin and MRF4 are in- 
duced  upon  differentiation  (57,  79),  MyoD  is  not  ex- 
pressed (5, 57). In contrast, the adult mouse C2C12 line 
expresses MyoD and myogenin (9, 11, 57), as well as both 
IGF-I and IGF-II (71, 72). This could explain why differ- 
entiation of the C2C12 cell line is less responsive to the ap- 
plication of exogenous IGFs (21). 
A  relationship between  IGF and  myogenic factor ex- 
pression was  established  by Florini and colleagues  (17). 
Their study showed that when rat L6 muscle cells were ex- 
posed to myogenin antisense oligomers, the cells became 
refractory to stimulation of differentiation by IGF-I, al- 
though  other anabolic stimulatory effects of the  growth 
factor were unaffected. Differentiation, as  measured by 
muscle creatine kinase levels, was proportional to the level 
of myogenin  gene  expression  induced  in  these  IGF-I- 
treated cells (21). In a complementary study, the introduc- 
tion of either IGF-I or IGF-II antisense oligonucleotides 
into C2C12 cells partially blocked differentiation, suggest- 
ing that both IGFs may play a critical role in myogenic dif- 
ferentiation (22). 
IGF-I is defined as a growth factor because of its mito- 
genic capability. Most cell lines characterized to date re- 
quire IGF-I for cell division (for review see 43). Specifi- 
cally, IGF-I is required for cells to traverse the G1 phase 
of the cell cycle, and it is therefore referred to as a progres- 
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the presence of, but is distinguished from, competence fac- 
tors that permit a cell to enter the G1 phase from the GO 
or quiescent phase (51).  In addition to a progression fac- 
tor, protein synthesis is also required to initiate the S phase 
of the cell cycle. If protein synthesis is blocked, the treat- 
ment of cells with IGF-I fails to elicit a procession through 
the "V checkpoint" of the G1 phase of the cell cycle (51). 
The role  of the  cell cycle in myogenesis has recently 
been  the subject of intensive study (for review see 40). 
Terminally differentiated skeletal muscle cells are thought 
to be irreversibly withdrawn from the cell cycle (49); i.e., 
fused, multinucleated myotubes no longer synthesize DNA 
or divide. Regulation of the cell cycle is governed, in part, 
by Rb, the retinoblastoma gene product. In particular, dif- 
ferentiated myotubes lacking Rb will continue to synthe- 
size DNA (64).  Additional regulation of the cell cycle is 
controlled by the cyclins, a  class of proteins believed to 
promote progression through the cell cycle by activating 
cyclin-dependent kinases (cdks). Among these, the D-type 
cyclins (D1, D2, and D3) have emerged as key regulators 
of the G1 phase of the cell cycle in eukaryotes (for review 
see 65). They presumably share overlapping but not com- 
pletely redundant activities, as evidenced by their tissue- 
specific distribution (for review see 65).  The ectopic ex- 
pression of one of these cyclins, cyclin D1, has also been 
shown to inhibit myogenic factor activation of muscle-spe- 
cific reporter constructs (56, 67). Conversely, the cell cycle 
inhibitor, p21, which is also known to bind to the cdks (27, 
32, 80),  can be activated by MyoD, and thus may play a 
role in linking myogenesis with cell cycle withdrawal (29, 
52, 67). 
It has been previously demonstrated that IGF-I stimu- 
lates both proliferation and myogenesis in the L6E9 cell 
line. The present study was undertaken in an attempt to 
resolve this paradoxical effect of IGF-I on myoblasts in tis- 
sue culture. To characterize the cell cycle events associ- 
ated with IGF-I stimulation of confluent L6E9 cells, we as- 
sayed the  mRNA  expression pattern  of nuclear factors 
during myogenesis. The transcript levels of D-type cyclins 
were initially stimulated by IGF-I, but at later time points 
these levels were diminished until they were equivalent to 
those of untreated cells. This mRNA expression pattern 
was the inverse of that for the myogenic factors, myogenin 
and MRF-4, which were initially repressed by IGF-I, but 
later were  equivalent to  the  expression  from untreated 
cells. The application of exogenous IGF-I to myoblasts re- 
sulted in larger myotubes and the activation of a myosin 
light chain reporter construct (MLCICAT). At 48 h  the 
IGF-I-treated cells expressed myogenin equivalent to the 
levels observed for untreated cells, despite having a prolif- 
erative response as great as cells maintained in growth me- 
dia (20% FCS). These data indicate that although IGF-I- 
treated myoblasts remain in the proliferative state longer, 
and therefore initiate fusion later, they exhibit an acceler- 
ated and enhanced myogenic response. 
Materials and Methods 
Cell Lines and Culture Conditions 
The L6E9 cell line, a subclone of the rat L6 neonatal cell line (81), was se- 
lected for its ability to fuse quickly into terminally differentiated myo- 
tubes (49). Cells were maintained as myoblasts by culturing in DME with 
20% FCS. Penicillin/streptomycin (GIBCO BRL, Gaithersburg, MD) was 
included in the media at 50 U/ml and 50 Ixg/ml. Cells were differentiated 
in  serum-free DME,  or  in  DME  supplemented with 2%  horse serum 
(HS), or DME supplemented with the indicated concentrations of IGF-I. 
IGF-I  (Ciba-Geigy, Research Triangle Park,  NC)  was generously pro- 
vided by J. Florini (Syracuse University, Syracuse, NY). 500 p,g/ml BSA 
was added with the IGF-I as described by Florini and Ewton (17). 
Immunohistology 
L6E9 cells were maintained and treated with IGF-I under the conditions 
described above. The cells were lysed with PBS/0.1% Triton X-100 and 
fixed in 100% methanol. After blocking with horse serum, cells were incu- 
bated with anti-myosin heavy chain (MHC) mAb, MF-20 (gift from D. 
Bader, Vanderbilt University, Nashville, TN), overnight at 4°C. Cells were 
then washed with PBS and treated with biotinylated secondary antibody, 
avidin, and biotinylated HRP according to the manufacturer's instructions 
(Vectastain ABC Kit; Vector Laboratories, Inc., Burlingame, CA). Cells 
were photographed with a  phase-contrast microscope (Nikon Inc., Gar- 
den City, NY). 
Expression Vectors, Transfections, and CAT Assays 
MLC1  promoter-CAT expression vectors  carrying the  173-bp  myosin 
light chain (MLC) enhancer (pCAT173) were described previously (76). 
Transfections of CAT reporter constructs and pSV-13-galactosidase nor- 
malizing vector  (catalogue  E1081;  Promega,  Madison,  WI)  were  per- 
formed by calcium phosphate coprecipitation as described previously (60). 
100-mm plates were transfected with 15 }xg of pCAT173 construct, the in- 
dicated amount of myogenic factor expression vector, pSV-13-galactosi- 
dase, and vector DNA for a  total of 30 Ixg DNA per plate.  Cells were 
switched to differentiation media 16 h after DNA/calcium phosphate pre- 
cipitate had been added and were harvested after an additional 48 h. CAT 
assays were performed using normalized amounts of cell extracts. Total 
protein was measured spectrophotometrically by reacting 1 p~l of cell ex- 
tract with protein assay dye reagent (catalogue 500-0006; Bio Rad Labora- 
tories, Hercules, CA ). 13-galactosidase  (13-gal) assays were performed on 
extract volumes normalized to the total protein concentration of each ex- 
tract. The 13-gal activities were then used to determine the volume of cell 
extract used in subsequent CAT assays. CAT assays were performed ac- 
cording to published protocols (60). 
Northern Analysis 
Total cellular RNA was isolated from L6E9 cells grown on tissue-culture 
plates using guanidinium lysis and CsC1 gradients. 20 p,g of RNA was 
loaded in each lane of a  1.5% agarose gel containing 5% formaldehyde 
and electrophoresed in a  1×  MOPS  (20 mM) buffer. RNA was trans- 
ferred to Zetabind nylon membrane (Cuno, Inc., Meriden, CT). Prehy- 
bridization and hybridization were performed overnight at 42°C in 50% 
formamide according to the manufacturer's instructions. Probes were pre- 
pared from full-length eDNA fragments using a multiprime DNA labeling 
kit (Amersham Corp., Arlington Heights, IL) to incorporate [et-s2p]dCTP 
(3,00(0-6,000  Ci/mmol) (New England Nuclear, Boston, MA). Ethidium 
bromide staining was used to verify equal loading. Quantitation of the 
Northerns was done using NIH Image software. 
DNA Synthesis Assays 
DNA synthesis was measured by [3H]thymidine uptake done according to 
published protocols  (18).  Briefly, 25  p,1 of [3H]thymidine (6.7 Cu/mM) 
(catalogue NET-027;  Dupont-New England Nuclear, Wilmington, DE) 
was added to each plate of tissue-culture cells, and cells were replaced in 
the incubator. To harvest, cells were washed twice with PBS, and then 
10% TCA was added to each plate for 5 rain. The plates were then washed 
twice with water, and 200 ixl of .25 M NaOH was added. Plates were then 
incubated for 1-2 h, scraped, and measured in a scintillation counter. 
4; 6-Diamidino-2-phenylindole (DAPI) 
Nuclear Staining 
DAPI  (catalogue 236  276)  was purchased from Boehringer Mannheim 
Biochemicals (Indianapolis, IN) and used according to the manufacturer's 
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ice-cold methanol for 5 min, and then washed in PBS two to three times 
to rehydrate. The plates were incubated in 1 p,g/ml of DAPI for 15 min, 
and then rinsed with PBS. Nuclear staining was visualized on an Axiophot 
microscope (Carl Zeiss, Inc., Thornwood, NY) with a DAPI filter. Eight 
separate randomly selected fields were counted to quantitate nuclei in 
each experimental group. 
Results 
IGF-I Enhances Myogenesis in L6E9 Myoblasts 
In the  present  study,  a  subclone  of the  original  L6 line 
(L6E9)  was used to study the molecular basis of IGF-I- 
accelerated myogenesis. The L6E9 subline was originally 
selected for its ability to fuse quickly, and the contractile 
protein isoforms it expresses have been characterized (26, 
48, 50). To examine the effects of IGF-I on the myogenic 
properties of the  L6E9  line, we differentiated  confluent 
L6E9 myoblast cultures  in  defined media containing  in- 
creasing amounts of IGF-I (see Materials and Methods). 
Clear differences in cell morphology were observed with 
the varying levels of IGF-I treatment. Cells in defined me- 
dia  that  contained  25  ng/ml or higher  concentrations  of 
IGF-I had larger multinucleated myotubes than those seen 
in control plates (Fig. 1). These morphological indicators 
of myogenesis were reduced at the highest IGF-I concen- 
trations  (150  ng;  data  not  shown),  but  they  were  still 
greater than in conditions lacking IGF-I. The biphasic re- 
sponse of myoblasts to IGF-I is in agreement with previ- 
ous  studies  in  which  enhanced  differentiation  by IGF-I 
was  demonstrated  by  increased  muscle  creatine  kinase 
gene expression in L6A1 cultures (19). Having established 
a similar response to IGF-I in the L6E9 subline, we used 
these cells for the subsequent experiments described be- 
low. In these studies, we focus on the response of conflu- 
ent L6E9 myoblasts to IGF-I. 
A  Transfected MLC Enhancer Is Activated in L6E9 
Myotubes by Exogenous IGF-I 
To investigate the molecular pathways involved in IGF-I- 
enhanced  myogenesis, we examined the  effect of exoge- 
nous IGF-I on the activation of a muscle-specific enhancer 
associated with the rat MLC 1/3 locus. This enhancer lies 
downstream of the genes encoding the MLC1 and MLC3 
isoforms (10, 63), which are transcribed from two differen- 
tially  regulated  promoters  with  accompanying alternate 
splicing pathways (53,  69).  The essential  role of the  en- 
hancer in activating MLC transcription has been demon- 
strated  in  muscle  cell  cultures  (10,  63,  76).  In  addition, 
transgenic  mice  carrying  a  CAT  reporter  linked  to  the 
MLC1 promoter and the downstream MLC enhancer ex- 
press the CAT transgene exclusively in skeletal muscle tis- 
sues (62).  Thus the  MLC enhancer constitutes a  marker 
for myogenesis and therefore a potential molecular target 
for the action of IGF-I. Since L6E9 cells do not normally 
express MLC1 (26, 50), they represent an ideal model for 
examining the possible activation of the MLC enhancer by 
exogenous stimuli. 
A  rat MLC1 promoter-CAT reporter construct, driven 
by  a  rat  MLC  enhancer  (pCAT173)  (76),  was  cotrans- 
fected with a pSV-lacZ normalizing vector into L6E9 myo- 
blasts. The transfected cells were differentiated in defined 
media containing varying concentrations  of IGF-I. Since 
IGF-I causes a  general increase in transcription and me- 
tabolism (1, 15,  18), f3-gal assays were normalized to pro- 
tein levels in the extracts, and then the amount of extract 
used in each CAT assay was normalized to these [3-gal val- 
ues. The action of IGF-I on the transfected CAT gene con- 
struct  could  therefore  be  distinguished  from  a  general 
stimulation of metabolic rates. As seen in Fig. 2, IGF-I in- 
duced expression from the pCAT173 construct in a titrat- 
able fashion. When treated with 100-150 p~g/ml of IGF-I, 
the  activity  from  pCAT173  demonstrated  an  approxi- 
mately fourfold induction over the activity from pCAT173 
in untreated cells. 
The MLC Enhancer Is Activated in L6E9 Myotubes by 
Forced Myogenin Expression 
Previous studies aimed at defining the role of myogenin in 
IGF-I-enhanced myogenesis have shown that exposure of 
L6A1 cells to exogenous IGF-I is accompanied by an in- 
crease in myogenin mRNA (21), and that stimulation of 
myogenesis in these cells is specifically blocked by an anti- 
sense  oligonucleotide  complementary  to  the  myogenin 
coding region  (17).  These results support the hypothesis 
that IGF-I-enhanced myogenesis operates through a path- 
way that  involves the  action  of myogenin.  Notably,  the 
L6E9 cell line used in this study expresses myogenin but 
not MyoD (5, 79). The inability of this cell line to activate 
the MLC enhancer during differentiation could therefore be 
due to the absence of MyoD: Thus, it can be envisioned 
that levels of active, endogenous myogenin in L6E9 cells 
may be below a  threshold  necessary to induce  MLC en- 
hancer activity. We therefore investigated whether an in- 
crease in intracellular myogenin concentration could acti- 
vate  the  MLC  enhancer  in  L6E9  cells.  The  pCAT173 
construct described above was cotransfected with increas- 
ing amounts of either MyoD or myogenin expression vec- 
tors into L6E9 cultures. As seen in Fig. 3, cotransfection of 
these cells with either a MyoD or a myogenin expression 
vector together with the MLC1 enhancer-CAT construct 
induced  CAT  activity.  Increasing  the  amounts  of  both 
myogenin and MyoD expression plasmid led to increased 
activity  from the  MLC  reporter  construct.  This  furthur 
suggested that myogenin may be involved in the IGF-I- 
induced activation of the MLC enhancer. MyoD is a less 
likely candidate  because it is not  expressed normally in 
L6E9 cells (5, 79). 
IGF-I Treatment Initially Represses Myogenin and 
MRF4 Expression  in L6E9 Cells 
To establish  a  relationship  between  the  action of IGF-I 
and the induction of MLC enhancer activity by myogenic 
factors, we investigated whether IGF-I increases accumu- 
lation of myogenic factor transcripts in L6E9 cultures. To- 
tal RNA was prepared from L6E9 cells harvested at differ- 
ent times after IGF-I treatment. Northern  blot analysis 
in Fig. 4 A  demonstrated an approximately threefold de- 
crease in myogenin transcripts after 1 h of IGF-I treatment 
(second and  third lanes from  the left), and  it  remained 
slightly repressed through 30 h of treatment. By 48 h, myo- 
genin  transcript  levels  were  equivalent  in  the  IGF-I- 
Engert et al. IGF-I, Mitogenesis, and Myogenesis  433 Figure 1.  IGF-I enhances myogenic differentiation of L6E9 ceils. Parallel cultures of L6E9 myoblasts were treated with different con- 
centrations of IGF-I in defined media (DME). After 48 h, the cultures were fixed and stained with an antibody against MHC (MF-20) as 
described in Materials and Methods. (a) Cells were differentiated in the absence of IGF-I. Cultures shown in b, c, and d were treated 
with 25, 50, and 100 ng/mt IGF-I, respectively.  Cultures shown in e are myoblasts maintained in growth medium. 
treated  and  the  untreated  cultures.  A  similar  decline  in 
MRF4  transcripts  was observed  (Fig.  4 A). MRF-4 tran- 
script levels, however, were still substantially repressed at 
30 h, but by 48 h, they had also become equivalent to that 
of untreated cells. Although already at low levels, the ex- 
pression of myf-5 mRNA was diminished (Fig. 4 A) as pre- 
viously reported  (44),  and  it  was  not  affected  by  IGF-I 
treatment.  These results are inconsistent with a  direct in- 
duction of myogenic markers  by IGF-I and indicate  that 
myoblasts have a multiphasic response to the growth factor. 
IGF Activates Cyclins D1 and D2 
To determine if markers of cell proliferation were affected 
by IGF-I treatment  of L6E9  myoblasts,  we  investigated 
the level of the mRNA of the D-type cyclins at early time 
The Journal of Cell Biology, Volume 135,  1996  434 Figure 2.  IGF-I induces MLC enhancer-driven CAT activity in 
L6E9  cells. L6E9  myoblasts transfected with  MLC-CAT con- 
struct pCAT173 were treated with increasing concentrations of 
IGF-I as indicated. Cultures were harvested at 48 h, and cell ex- 
tracts used for CAT assays were normalized to 13-gal activity ad- 
justed for total protein (as measured by Bradford assay). Results 
are  expressed as fold induction relative to  untreated  cultures. 
Values are the average of at least three experiments (with stan- 
dard error). 
points. It has previously been demonstrated that the D-type 
cyclins respond to growth factors (25, 45, 77, 78). In addi- 
tion, cyclin D1 has recently been implicated in the repres- 
sion of myogenic factor transactivation of muscle-specific 
genes in 10T1/2 cells (56, 67). As seen in Fig. 3, transcripts 
encoding cyclins D1  and D2 increased by 1 h  after treat- 
ment  with  IGF-I, and  a  substantial  increase  was  main- 
tained through 8 h  after treatment. After 30 h  of treatment, 
the level of cyclin D1 and D2 expression was equivalent to 
that of the untreated cells. Transcripts encoding cyclin D3, 
which has been previously shown to increase during myo- 
genesis in L6 cells (39), were not affected by IGF-I during 
this time period. An additional cell cycle regulator, p21, in- 
hibits cell cycle progression by binding to cdk complexes 
Figure 3.  Cotransfection of either MyoD or myogenin transacti- 
vates the  MLC enhancer in  L6E9  cells. L6E9  myoblasts were 
cotransfected with pCAT173 and either a MyoD (shaded bars) or 
myogenin (black bars) expression vector. Results are expressed 
as  fold  induction  relative  to  cultures  transfected  with  vector 
DNA alone. Each value (with standard error) represents the av- 
erage of at least two experiments. 
Figure 4.  IGF-I modulates accumulation of transcripts encoding 
markers of myoblast proliferation and differentiation. (A) Total 
RNA, extracted from L6E9 cells, either untreated (-), or treated 
with IGF-I (+), was analyzed by Northern blots with the indi- 
cated 32p-labeled probes. The  leftmost lane shows RNA from 
confluent L6E9 cells maintained in 20%  FCS (0).  At this time 
point, other plates were shifted to DME alone (-) or DME with 
IGF-I (+) and harvested after the indicated times. The low levels 
of myogenin and MRF-4 seen in the lane representing the 0 time 
point are a result of the confluency of the L6E9 cultures. (B) The 
results for four of the transcripts shown in Fig. 4 A  (myogenin, 
MRF-4, cyclin D1, and cyclin D2) were quantified by densitometric 
scan. The level of mRNA was plotted from IGF-I-treated L6E9 
cells relative to the level from untreated cells at each time point. 
Engert et al. IGF-I, Mitogenesis, and Myogenesis  435 Figure 5.  IGF-I stimulates  DNA synthesis in the absence of se- 
rum. L6E9 myoblasts were incubated for 16 h with [3H]thymidine 
in either 20% FCS (GM), 2% HS (DM), IGF-I (IGF), or DME 
alone (-). Incorporated [3H]thymidine was measured over two 
time frames, 4-20 h (black bars) and 24-40 h (shaded bars). Re- 
suits are expressed relative to the cultures in DME alone during 
the 4-20-h time frame. Values are the mean of three experiments 
(with standard error). 
(27, 32, 80), and its induction has recently been correlated 
with myogenesis (28, 29, 39, 52). In our experiments, how- 
ever, no change was seen in p21 expression in the 48 h af- 
ter treatment with IGF-I (Fig. 4 A). 
IGF-I Treatment Stimulates DNA Synthesis 
Since an increase in D-type cyclin transcripts is usually in- 
dicative of passage through the cell cycle, we determined 
[3H]thymidine uptake experiments over two time periods 
after IGF-I treatment, as a measure of the extent of DNA 
synthesis.  The  results  shown  in  Fig.  5  demonstrate  that 
IGF-I was a potent stimulator of DNA synthesis in conflu- 
ent L6E9 cells. IGF-I treatment had the equivalent effects 
of 20% FCS in this assay during both the early time period 
(4--20 h)  and the later time period  (24-40 h)  after IGF-I 
stimulation.  In  contrast,  ceils  differentiated  in  2%  HS 
demonstrated  no  increase  in  [3H]thymidine  uptake  over 
basal  levels.  Thus,  IGF-I  stimulates  DNA  synthesis  in 
L6E9 myoblasts even when applied to confluent cells. 
IGF-I Treatment Initially Promotes Cell Division of 
L6E9 Myoblasts 
To  assess  the  cumulative  effects of the  increased  DNA 
synthesis observed in Fig. 5, we measured the increase in 
nuclei caused by IGF-I treatment. Confluent L6E9 myo- 
blasts were stained with DAPI at 24 h and 48 h after IGF-I 
treatment. These experiments indicated that the increased 
DNA synthesis observed in IGF-I-treated cells correlates 
with an increased proliferation after 24 h (Fig. 6). At 24 h, 
the number of nuclei in IGF-I-treated cultures was signifi- 
cantly greater than cells cultured in either 2% HS supple- 
mented  media or  in  DME  alone  but  only slightly more 
than  the  number in 20%  FCS-treated  cultures.  By 24 h, 
some fusion and myotube formation could be seen in the 
Figure 6.  IGF-I stimulates  L6E9 cells to divide, but not all the 
cells survive. L6E9 myoblasts, passaged in 20% FCS, were trans- 
ferred to either 20% FCS (GM), 2% HS (DM), IGF-I (IGF), or 
in DME alone (-). Cell cultures  were stained  with DAPI at ei- 
ther 24 h (black bars) or 48 h (shaded bars). The nuclei in eight 
randomly selected  fields were counted in each experiment.  Val- 
ues are the mean of three experiments (with standard error). 
DME and 2%  HS cultures plates, but no fusion was ob- 
served in the 20% FCS or IGF-I-treated plates (data not 
shown).  After  48  h,  the  IGF-I-treated cells  had  N50% 
fewer nuclei than after 24 h  of treatment. The 20% FCS, 
2% HS, and DME cultures did not exhibit this extensive 
reduction in nuclei (Fig. 6). Thus, the enhanced myogene- 
sis demonstrated in Fig.  1 was accompanied by a  signifi- 
cant reduction in the total number of nuclei that was not 
seen in the other treatment groups. 
The IGF-I stimulation of myogenesis is not due to mito- 
gen depletion. To assess the possibility that the enhanced 
myogenesis induced  by IGF-I was  the  indirect  result  of 
proliferating cells gradually depleting the media of IGF-I, 
experiments  were  performed in  which  IGF-I was  reap- 
plied  every  12  h  to  the  differentiating  L6E9  cells.  The 
myogenesis that  resulted  from the  addition  of IGF-I to 
cells only once was compared to cells to which fresh IGF-I- 
containing media was added every 12 h. As shown in Fig. 7, 
the  further  addition  of fresh  IGF-I stimulated  an  even 
greater myogenic response at 48 h  (C) than the single ap- 
plication of IGF-I (B). This indicates that the myogenic ac- 
tivity of IGF-I is not due to mitogen depletion, but rather 
that it participates directly in regulating myogenic differ- 
entiation. 
Discussion 
In this study, we have identified specific mitogenic mark- 
ers that are expressed before the myogenesis induced by 
IGF-I in  L6E9  cells.  Several lines  of evidence implicate 
proliferation as a precursor to myogenesis during IGF-I- 
stimulated differentiation.  First, cyclin D1  and cyclin D2 
were  activated within  the  first hour  of IGF-I treatment. 
Second, IGF-I caused the cells to go through the S phase 
of the cell cycle as demonstrated by tritiated thymidine up- 
take experiments. Third, as demonstrated by DAPI stain- 
ing, the  IGF-I-treated cells completed another round  of 
the  cell  cycle  and  possesed  more  nuclei  than  untreated 
The Journal of Cell Biology, Volume 135, 1996  436 Figure 7.  Myogenic stimulation  by IGF-I is not dependent on 
IGF-I depletion. Confluent L6E9 myoblasts were switched to ei- 
ther DME alone (A) or DME supplemented with 100 ng/ml IGF-I 
(B and C). One experimental  group was treated with additional 
IGF-I every 12 h (C). After 48 h, the cells were fixed and photo- 
graphed. 
cells at 24 h after treatment. Fourth, the transcriptional ac- 
tivation of the myogenin and MRF4 genes was delayed in 
IGF-I-treated L6E9 cells. Although the levels of myoge- 
nin  and  MRF-4  are  initially suppressed  by IGF-I treat- 
ment, the levels after 48 h  of treatment are equivalent to 
those of untreated cells, indicating that this suppression is 
followed  by  an  accelerated  progression  of  myogenesis. 
The activation of myogenic factor expression appeared to 
be inversely correlated with the expression of cyclin D1 
and D2 (Fig. 4 B). Thus, the balance of nuclear factors, 
both proliferative and myogenic, may play a critical role in 
the final steps of the signaling pathway initiated by IGF-I. 
Taken together with previous findings, the present study 
indicates that the myogenesis stimulated by IGF-I occurs 
later than, but is perhaps dependent on, the earlier mito- 
genic stimulation. 
In contrast with myoblasts cultured in DME alone, myo- 
blasts  treated  with  IGF-I  resulted  in  the  formation  of 
larger myotubes, despite their later exit from the cell cycle. 
IGF-I, like insulin, causes an increase in protein synthesis 
and a concurrent decrease in protein degradation in myo- 
blasts  (15,  58).  Here we  demonstrate  that  treatment  of 
L6E9 myoblasts with increasing amounts of IGF-I results 
in increased cellular hypertrophy (Fig. 1). This effect is not 
limited to skeletal muscle cells, as IGF-I expression corre- 
lates with hypertrophy in smooth muscle (6) and induces 
hypertrophy in  cardiomyocytes  (34).  The  IGF-I-stimu- 
lated  hypertrophy of L6E9  myotubes is  consistent  with 
earlier work that demonstrated that primary avian myofi- 
bers  undergo  hypertrophy when  stimulated  with  IGF-I 
(74). In addition, Schwartz and colleagues have shown that 
muscle-specific expression of an IGF-I transgene results in 
hypertrophied muscles (7). 
It has been demonstrated that DNA synthesis and cell 
division are not prerequisites for the myogenic effect of 
IGF-I (73). In fact, recent work suggests that the mitogenic 
effect of IGF-I actually may delay myogenesis. Florini and 
colleagues recently demonstrated that myogenic cells plated 
at a  higher density have a  greater myogenic response to 
IGF-I than cells plated at a lower density (16). These au- 
thors hypothesize that the increased response to IGF-I by 
cells plated at high density was actually due to the inhibi- 
tion of mitogenesis, allowing for earlier myogenesis. How- 
ever, the increase in cell density caused by the IGF-I-stim- 
ulated mitogenesis could also contribute to an increase in 
myogenic cell-cell contacts, thereby enhancing the IGF-I 
stimulation  of myogenesis seen in  this  study and  in  the 
present one. 
Quinn and Roh have also demonstrated that in L6 cells 
overexpressing the IGF-I receptor, high concentrations of 
IGF-I led to an increased mitogenic response and, in fact, 
prevented the cells from forming myotubes (54). This is in 
agreement with other studies demonstrating that at high 
doses of IGF-I, when L6 cells exhibit maximum prolifera- 
tion, the  stimulated  differentiation was  less  than  at  low 
concentrations (19). The number of IGF-I receptors has 
been shown to increase in myoblasts during differentiation 
(71). Thus, it is possible that the mitogenic and myogenic 
activities of IGF-I are mediated by both the IGF-I concen- 
tration and the IGF-I receptor density. 
In  this work, we demonstrated that the high doses of 
IGF-I,  even when  reapplied  to  cells,  resulted  in  an  en- 
hanced myogenesis (Fig. 7). This is in agreement with pre- 
vious work that demonstrated an even greater stimulation 
of myogenin, and no increase in Rb phosphorylation when 
IGF-I is reapplied after 24 h  (61). Thus, the myogenic ef- 
fect of IGF-I was not due to the proliferating cells deplet- 
ing the media of IGF-I. 
A  candidate for mediating the myogenic induction by 
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in IGF-I-treated L6E9 cells, where the MLC locus is nor- 
mally inactive, is a further indication of an increased myo- 
genic response that could depend on myogenin. We have 
previously demonstrated that exogenously expressed myo- 
genin can  activate  the  MLC enhancer in  NIH3T3  cells 
(76), and in this study we show that myogenin can activate 
it in L6E9 cells (Fig. 3).  In addition, earlier work impli- 
cated myogenin in the induction of differentiation by IGF-I 
(17, 21). In the present study, however, the expression of 
myogenin in  IGF-I-treated  L6E9  cells  was  actually re- 
pressed as early as 1 h  after treatment, and at 48 h was 
only equivalent to  the  expression  from untreated  cells. 
Only at later time points did the level of myogenin mRNA 
in IGF-I-treated cells ever exceed the level in untreated 
cells (data not shown). These data are consistent with the 
initial repression and later recovery of myogenin expres- 
sion seen by Rosenthal and Cheng (61). Although myoge- 
nin mRNA increased in untreated L6E9 cells, this was not 
accompanied by the larger myotubes and increased mus- 
cle-specific gene activity characterizing L6E9 cells treated 
with IGF-I (23)  (Figs. 1 and 2). Taken together, these re- 
suits demonstrate that myogenin expression is necessary 
but  clearly not  sufficient for  the  enhanced myogenesis 
caused by IGF-I. 
Myoblasts  may require  the  continuous  repression  of 
myogenic factors below a threshold level to complete the 
cell cycle. Cyclin D1 has been shown to repress the activity 
of MyoD (56,  67)  and of myogenin (56) in 10T1/2  cells. 
The early repression of myogenin and MRF-4 transcripts 
observed in this study coincides with the accumulation of 
cyclin D1 and D2 mRNA. In this report, we have demon- 
strated that the mRNA levels of cyclin D1 and cyclin D2 
are induced within the first hour of treatment by IGF-I, 
with the peak of expression occurring between 2 and 5 h 
after  treatment.  Rosenthal  and  Cheng have  also  found 
that  IGF-I  also  stimulated the  expression  of cyclin D1 
mRNA in L6 cells (61).  Consistent with these results, it 
has been shown that in other cell lines, cyclin D1 and D2 
respond to mitogenic signals (45, 77, 78), including IGF-I 
(25). Other studies (35, 55, 75) have demonstrated that ex- 
pression of cyclin D1 mRNA is reduced to very low or un- 
detectable levels at later stages of myogenesis. The initial 
stimulus by IGF-I is similar to the response of myoblasts to 
FGF in which cyclin D1 also increased significantly by 4 h 
after treatment (55). However, in contrast with the effects 
of IGF-I, the expression of myogenic factors remains re- 
pressed in FGF-treated cells, and these cells do not go on 
to become myotubes and do not express the muscle-spe- 
cific marker MHC (55).  Thus, a balance between growth 
and differentiation in myoblasts could be mediated by the 
sequential activation of nuclear factors responding specifi- 
cally to IGF-I. 
We  detected  no  consistent  change  in  the  expression 
level of p21  mRNA during the 48 h  of IGF-I treatment 
(Fig.  3).  Recently, a  correlation has  been  observed  be- 
tween the expression of myogenic factors and cdk inhibi- 
tors, such as p21, that prevent passage through the cell cy- 
cle. The expression of p21  was shown to increase during 
myogenesis in C2C12 cells (28, 29, 52)and can be activated 
by the myogenic factor MyoD in CV1 cells (29). However, 
in a similar study, Hamel and colleagues showed that p21 
mRNA is not induced in L6 cells until after 48 h in differ- 
entiation media (39). Thus, while p21 may still play a role 
in the terminal differentiation of L6E9 cells¢it is likely that 
its effect takes place after the myogenic program is well es- 
tablished. 
The steep decline in the total number of nuclei in the 
IGF-I-treated plates after 48 h was an unexpected result. 
It is not clear what contributes to this decline, but it is pos- 
sible that only the cells that divided survived. This idea is 
supported by the fact that the tritiated thymidine uptake 
in the IGF-I-treated plates was equivalent to the plates 
cultured in 20%  FCS even though these plates  demon- 
strated no cell death or myogenesis. Although apoptosis 
has recently been implicated in myogenesis (47), most re- 
ports support IGF-I's role in preventing apoptosis (2, 33). 
Additionally,  IGF-II  has  been  shown  to  inhibit  pro- 
grammed cell  death  in  the  muscles  of mdx  mice  (68). 
Whatever the source of the cell death seen in this study, it 
does not preclude the robust myogenesis seen in IGF-I- 
treated  L6E9  cells.  It  remains  a  formal possibility that 
IGF-I treatment could select for a more myogenic subset 
of the parental line; however, the initial proliferative re- 
sponse to IGF-I, equivalent to the levels of proliferation 
induced by serum, argues against this interpretation. 
The results presented in this study have potentially im- 
portant implications for the developmental induction of 
the myogenic phenotype. During mammalian embryogen- 
esis, IGF-I expression is very low in most tissues, although 
IGF-I receptor mRNA is present in muscle (4). In particu- 
lar,  myogenic cells  are  only weakly positive  for  IGF-I 
mRNA in the embryo (3, 30, 31) and in the neonate (37). 
Nevertheless, Han et al. (31) found the IGF-I peptide lo- 
calized to embryonic myoblasts, even though there was no 
detectable mRNA expression. They concluded that even 
at these early stages, IGF-I could be released from neigh- 
boring  cells  and  absorbed  by IGF-I receptors  on  myo- 
blasts. This conclusion was supported by their finding that 
connective tissue surrounding skeletal muscles was found 
to be positive for IGF-I mRNA (12, 30, 31). The important 
role of the IGFs in development was further highlighted 
by  the  phenotype  of mice  lacking the  IGF-I  receptor. 
These mice failed to develop to their full size, remaining 
~60% of the size of normal mice from birth onward (42). 
In particular, a reduction in the number of myocytes was 
observed in this study. Interestingly, targeted mutation of 
the cyclin D1 gene also displayed a phenotype of reduced 
growth, among other defects (66). The developmental co- 
ordination of cell division and myogenesis may depend on 
the  response  of myogenic cells to  the  timed release  of 
IGF-I. 
The general distribution of IGF-I expression suggests 
that it may play an important role in tissue-specific meta- 
bolic functions, not only in development but also in the 
adult mammal through autocrine and/or paracrine path- 
ways (for review see 8).  One such paracrine function of 
IGF-I is muscle regeneration. In adult muscle tissue, IGF-I 
may coordinate the synchronous differentiation of satellite 
cells in response to muscle injury. Increased transcription 
of IGF-I and accumulation of the peptide has been docu- 
mented in regenerating muscle (13, 36, 38), where it pre- 
sumably acts locally as atrophic factor for the recruitment 
of satellite cells into the differentiation process, In addi- 
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increased levels of MyoD and myogenin mRNA  (24). It 
may well be that IGF-I causes proliferation first and then 
differentiation: a  sequence of events perfectly timed for 
the repair of injury by stem cells. 
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